Table 1. Characteristics of 133 GC patients and 109 normal controls enrolled in the study.
|
Training stage (n = 60) |
Testing stage (n = 132) |
External validation stage (n = 50) |
||||
|---|---|---|---|---|---|---|
| Variables | Cases (%) | Controls (%) | Cases (%) | Controls (%) | Cases (%) | Controls (%) |
| Number | 30 | 30 | 71 | 61 | 32 | 18 |
| Gender | ||||||
| Male | 20 (66.7) | 18 (60) | 42 (59.1) | 37 (60.7) | 21 (65.6) | 11 (61.1) |
| Female | 10 (33.3) | 12 (40) | 29 (40.9) | 24 (39.3) | 11 (34.4) | 7 (38.9) |
| Age | ||||||
| <60 | 13 (43.3) | 12 (40) | 33 (46.5) | 26 (42.7) | 15 (46.9) | 8 (44.4) |
| ≥60 | 17 (56.7) | 18 (60) | 38 (53.5) | 35 (57.3) | 17 (53.1) | 10 (55.6) |
| Location | ||||||
| Proximal | 7 (23.3) | 20 (28.2) | 11 (34.4) | |||
| Middle | 12 (40) | 33 (46.5) | 12 (37.5) | |||
| Distal | 11 (36.7) | 18 (25.3) | 9 (28.1) | |||
| Differentiation | ||||||
| Well | 6 (20) | 19 (26.8) | 8 (25) | |||
| Moderately | 11 (36.7) | 28 (39.4) | 13 (40.6) | |||
| Poorly | 13 (43.3) | 24 (33.8) | 11 (34.4) | |||
| T classification | ||||||
| T1 | 4 (13.3) | 16 (22.5) | 8 (25) | |||
| T2 | 4 (13.3) | 14 (19.7) | 4 (12.5) | |||
| T3 | 5 (16.7) | 15 (21.1) | 7 (21.9) | |||
| T4 | 17 (56.7) | 26 (36.7) | 13 (40.6) | |||
| N classification | ||||||
| N0 | 5 (16.7) | 17 (23.9) | 9 (28.1) | |||
| N1 | 8 (26.7) | 18 (25.4) | 7 (21.9) | |||
| N2 | 10 (33.3) | 19 (26.8) | 5 (15.6) | |||
| N3 | 7 (23.3) | 17 (23.9) | 11 (34.4) | |||
| Metastasis | ||||||
| M0 | 27 (90) | 62 (87.3) | 28 (87.5) | |||
| M1 | 3 (10) | 9 (12.7) | 4 (12.5) | |||
| TNM stage | ||||||
| I | 8 (26.7) | 13 (18.3) | 6 (18.8) | |||
| II | 5 (16.7) | 14 (19.7) | 5 (15.6) | |||
| III | 14 (46.6) | 35 (49.3) | 17 (53.1) | |||
| IV | 3 (10) | 9 (12.7) | 4 (12.5) | |||